Experienced in Acrocephalopolydactyly

Alain Hendlisz

Brussels, BRU, BE 
Experienced in Acrocephalopolydactyly
Brussels, BRU, BE 
OverviewLocationsClinical Research

Overview

Alain Hendlisz practices in Brussels, Belgium. Mr. Hendlisz is rated as an Experienced expert by MediFind in the treatment of Acrocephalopolydactyly. His top areas of expertise are Colorectal Cancer, Liver Cancer, Febrile Neutropenia, Hepato-Pancreato-Biliary Surgery, and Hepatectomy.

His clinical research consists of co-authoring 141 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Acrocephalopolydactyly.

Gender
Male

Locations

Brussels, BRU, Belgium
Other Locations
Rue Meylemeersch 90, Anderlecht, BRU 1070, Belgium
Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL
INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL
Enrollment Status: Completed
Publish Date: July 31, 2025
Intervention Type: Drug, Procedure
Study Drugs: Cisplatin, 5-fluorouracil or Capecitabine, Trastuzumab, Pertuzumab
Study Phase: Phase 2
An Open-label Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer
An Open-label Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer
Enrollment Status: Terminated
Publish Date: February 28, 2024
Intervention Type: Biological
Study Drug: NKR-2 Cells
Study Phase: Phase 1
Preoperative Chemosensitivity Testing as Predictor of Treatment Benefit in Adjuvant Stage III Colon Cancer: PePiTA Trial
Preoperative Chemosensitivity Testing as Predictor of Treatment Benefit in Adjuvant Stage III Colon Cancer: PePiTA Trial
Enrollment Status: Completed
Publish Date: August 07, 2023
Intervention Type: Drug
Study Drug: FOLFOX
Study Phase: Not Applicable
Correlating the Tumoral Metabolic Progression Index Measured by Serial FDG PET-CT and Apparent Diffusion Coefficient Measured by MRI to Patient's Outcome in Advanced Colorectal Cancer
Correlating the Tumoral Metabolic Progression Index Measured by Serial FDG PET-CT and Apparent Diffusion Coefficient Measured by MRI to Patient's Outcome in Advanced Colorectal Cancer
Enrollment Status: Completed
Publish Date: October 26, 2021
Intervention Type: Other
Study Phase: Not Applicable
An Open Label, Single Arm Pilot Study of OncoSil™, Administered to Study Participants With Unresectable Locally Advanced Pancreatic Adenocarcinoma, Given in Combination With FOLFIRINOX or Gemcitabine+Nab-paclitaxel Chemotherapies
An Open Label, Single Arm Pilot Study of OncoSil™, Administered to Study Participants With Unresectable Locally Advanced Pancreatic Adenocarcinoma, Given in Combination With FOLFIRINOX or Gemcitabine+Nab-paclitaxel Chemotherapies
Enrollment Status: Completed
Publish Date: July 13, 2021
Intervention Type: Device
Study Phase: Not Applicable
A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Enrollment Status: Terminated
Publish Date: July 15, 2020
Intervention Type: Drug
Study Phase: Phase 1
An Open-label, Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2, Administered Concurrently With the Neoadjuvant FOLFOX Treatment in Patients With Potentially Resectable Liver Metastases From Colorectal Cancer
An Open-label, Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2, Administered Concurrently With the Neoadjuvant FOLFOX Treatment in Patients With Potentially Resectable Liver Metastases From Colorectal Cancer
Enrollment Status: Unknown
Publish Date: June 16, 2020
Intervention Type: Biological
Study Drug: NKR-2 Cells
Study Phase: Phase 1
View 6 Less Clinical Trials

141 Total Publications

Are epigenetic-targeting approaches ready for prime time in neuroendocrine neoplasms?
Are epigenetic-targeting approaches ready for prime time in neuroendocrine neoplasms?
Journal: Current opinion in oncology
Published: May 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hendlisz's expertise for a condition
ConditionClose
    View All 27 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile